(BKLN) Senior Loan - Overview
Exchange: NYSE ARCA •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US46138G5080
Etf: Loans, Debt, Fixed Income
Total Rating 41
Risk 72
Buy Signal -0.03
| Risk 5d forecast | |
|---|---|
| Volatility | 6.38% |
| Relative Tail Risk | -1.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -0.55 |
| Character TTM | |
|---|---|
| Beta | 0.106 |
| Beta Downside | 0.118 |
| Drawdowns 3y | |
|---|---|
| Max DD | 3.55% |
| CAGR/Max DD | 2.32 |
Risks
Technicals:
low_hurst
Description: BKLN Senior Loan March 04, 2026
BKLN is an ETF that invests primarily in institutional leveraged loans. Leveraged loans are debt instruments issued by companies with significant existing debt or a poor credit history; they typically have floating interest rates, making them attractive in rising rate environments.
The fund tracks an index compiled by Morningstar, focusing on the largest leveraged loans weighted by market value, spreads, and interest payments. This market-weighted approach means larger, more liquid loans have a greater impact on the indexs performance.
To further understand BKLNs holdings and historical performance, consider exploring its detailed analytics on ValueRay.
Headlines to watch out for
- Rising interest rates boost floating-rate loan income
- Corporate default rates impact loan portfolio value
- Investor demand for senior loans fluctuates with economy
- Regulatory changes affect leveraged lending market
What is the price of BKLN shares?
As of March 10, 2026, the stock is trading at USD 20.51 with a total of 36,890,381 shares traded.
Over the past week, the price has changed by +1.48%, over one month by -0.34%, over three months by -0.82% and over the past year by +5.37%.
Over the past week, the price has changed by +1.48%, over one month by -0.34%, over three months by -0.82% and over the past year by +5.37%.
Is BKLN a buy, sell or hold?
Senior Loan has no consensus analysts rating.
What are the forecasts/targets for the BKLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |